Gonadorelin Acetate
Evidence: B — Meaningful Human EvidenceHormone / Fertility
Key facts
- Research areaHormone / Fertility
- Study records65 human
- Last updated2026-07-26
Evidence Snapshot
Regulatory Context
FDA records show historical approval of Lutrepulse (gonadorelin acetate) for induction of ovulation in hypothalamic amenorrhea. Current U.S. marketing availability and product status require separate verification before publication.
In Plain English
A quick, research-focused overview. It does not replace, and cannot outrank, the detailed evidence below.
What is it?
Gonadorelin acetate is a synthetic GnRH salt studied and historically used in pulsatile reproductive-endocrine therapy and diagnostic stimulation testing.
Why are researchers interested in it?
Research has evaluated pulsatile GnRH for hypothalamic amenorrhea and congenital hypogonadotropic hypogonadism, and single-dose stimulation tests for pituitary response.
What does the evidence look like?
Evidence grade B/C. Human, preclinical, regulatory, review, and anecdotal evidence must remain separated.
Biggest things to know
Clinical meaning depends strongly on pulse pattern, route, duration, and diagnosis. Historical approval does not prove that a currently marketed U.S. product is available.
Research Takeaway
Gonadorelin is synthetic native gonadotropin-releasing hormone (GnRH), a decapeptide that stimulates pituitary LH and FSH release when delivered in a physiologic pulsatile pattern; it is distinct from long-acting GnRH agonists such as leuprolide and nafarelin.
Evidence boundary: Continuous or long-acting GnRH-agonist exposure can produce different and even suppressive endocrine effects, so these drugs must not be conflated.
See all 6 evidence claims →Quick Summary
Gonadorelin acetate is a synthetic GnRH salt studied and historically used in pulsatile reproductive-endocrine therapy and diagnostic stimulation testing.
Mechanism & Research Overview
Gonadorelin is synthetic gonadotropin-releasing hormone. Pulsatile exposure can stimulate pituitary LH and FSH secretion, while a diagnostic bolus can test pituitary gonadotroph responsiveness.
Mechanism pathway
Relationship-support labels describe the type and directness of the research available, not proof of safety or effectiveness. Indirectly supported, inferred and uncertain relationships are not equivalent to directly supported ones.
- CompoundGonadorelin Acetate
- Directly supported (Directly supported relationship)Biological targetGnRH receptorReceptor
- Leads toPathwayReproductive & Endocrine Signaling
- Contributes to
- Biological processLH/FSH secretion
Relationship details
- Gonadorelin Acetate → GnRH receptor — Directly supportedPulsatile gonadorelin exposure stimulates pituitary LH and FSH secretion.
- LH/FSH secretion — contributes to the pathway (structural link, no support rating)Sources: src-gnrh-001
A biological process is not the same as a proven health or treatment outcome.
Relevant tissue/system context: Anterior pituitary gonadotrope
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Gonadorelin is synthetic native gonadotropin-releasing hormone (GnRH), a decapeptide that stimulates pituitary LH and FSH release when delivered in a physiologic pulsatile pattern; it is distinct from long-acting GnRH agonists such as leuprolide and nafarelin.
Does not establish
Evidence boundary: Continuous or long-acting GnRH-agonist exposure can produce different and even suppressive endocrine effects, so these drugs must not be conflated.
Supported
Pulsatile native GnRH has human evidence for restoring gonadotropin secretion and gonadal function in selected patients with hypothalamic hypogonadotropic hypogonadism.
Does not establish
Evidence boundary: These results depend on diagnosis and pulsatile delivery and do not establish benefit for routine TRT adjunct use or nonspecific testosterone enhancement.
Supported
FDA compounding documents identify gonadorelin acetate as a substance that has been a component of FDA-approved drug products, but this frozen package does not establish the availability of a currently marketed FDA-approved human gonadorelin finished product as of August 11, 2026.
Does not establish
Evidence boundary: Historical approved-drug status must not be simplified into a claim that every current compounded gonadorelin product is FDA-approved.
Supported
The safety and endocrine effects of gonadorelin are strongly dependent on delivery pattern, because pulsatile stimulation and sustained GnRH-receptor stimulation can have materially different physiological consequences.
Does not establish
Evidence boundary: This mechanistic distinction does not quantify the adverse-event profile of any specific compounded product.
Supported
Evidence from pulsatile GnRH treatment of diagnosed hypothalamic hypogonadism does not establish gonadorelin as a proven substitute for hCG in men receiving exogenous testosterone.
Does not establish
Evidence boundary: The absence of direct equivalence evidence prevents transferring fertility or testicular-maintenance claims between these therapies.
Supported
Only named clinical-study or historical approved-label dosing may appear as Study/Trial Dosing; consumer pump schedules, TRT-adjunct dosing, reconstitution, or injection guidance are prohibited.
Does not establish
Evidence boundary: Historical clinical dosing is descriptive evidence, not a current individualized recommendation.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Rare anaphylaxis after intravenous gonadorelin acetate has been reported.Safety Consideration
Pulsatile fertility treatment can produce multiple pregnancy and requires specialist monitoring.Safety Consideration
Continuous and pulsatile GnRH exposure can have different endocrine effects; they must not be conflated.
Research Areas Being Studied
Research areas discussed on this page reflect the Hormone / Fertility category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
Show findings from 5 human studies
- Pulsatile gonadorelin treatment in males with congenital hypogonadotropic hypogonadism (2024):
- Pituitary response to GnRH stimulation tests in different FSHB genotypes (2021):
- Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty (2015):
- Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone in hypothalamic amenorrhea (1990):
- Two-year comparison of pulsatile GnRH and gonadotropin therapy in men with hypogonadotropic hypogonadism (1988):
Study Tables by Evidence Type
6 study records
Human Studies & Clinical Data(5)
Pulsatile gonadorelin treatment in males with congenital hypogonadotropic hypogonadism
2024PMID 39210488
- Population / Model
- Males with congenital hypogonadotropic hypogonadism
- Dose / Duration / Finding
Pulsatile gonadorelin was associated with gonadotropin, testosterone, and spermatogenic responses in an observational clinical cohort.
- Study/Trial Dosing:
- Pulsatile gonadorelin doses of approximately 7 to 15 micrograms were reported in the cohort.
- Duration:
- Average treatment duration about 19 months.
Safety note
Long-term specialized treatment; findings do not justify unsupervised use.
Pituitary response to GnRH stimulation tests in different FSHB genotypes
2021PMID 33704441
- Population / Model
- Adults undergoing 100 microgram intravenous gonadorelin-acetate stimulation testing
- Dose / Duration / Finding
In a retrospective diagnostic study of 67 male subjects undergoing GnRH stimulation testing, peak LH response was significantly higher in FSHB-211 TT-genotype carriers than in GT or GG carriers; stimulated FSH levels did not differ significantly by genotype in the main analysis, though a smaller time-course interaction suggested an attenuated FSH response in T-allele carriers. The study's authors cautioned that its retrospective design and small number of TT carriers warrant caution in interpretation. The study evaluated pituitary physiology and genotype-related response, not chronic treatment efficacy.
Show full finding- Study/Trial Dosing:
- 100 micrograms intravenous gonadorelin acetate in the described stimulation test.
- Duration:
- Acute diagnostic test.
Safety note
Diagnostic-test study; not evidence for chronic treatment.
Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty
2015PMID 26197466
- Population / Model
- Single pediatric case during intravenous diagnostic administration
- Dose / Duration / Finding
In a published case report, an 8-year-old girl with central precocious puberty, previously treated uneventfully with triptorelin acetate for about six months, experienced a severe reaction -- including loss of consciousness and tonic seizures -- within approximately three minutes of an intravenous gonadorelin acetate diagnostic (LH-RH) stimulation test; the episode was clinically characterized as anaphylaxis.
Show full finding
Safety note
Rare but potentially life-threatening hypersensitivity is documented by this case report.
Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone in hypothalamic amenorrhea
1990PMID 2122733
- Population / Model
- Women with hypothalamic amenorrhea treated in a multicenter program
- Dose / Duration / Finding
In a multicenter program of 109 women with primary or secondary hypothalamic amenorrhea, intravenous pulsatile gonadorelin (Lutrepulse) produced ovulation in 91% and 96% of patients respectively, with efficacy considered comparable to human menopausal gonadotropins.
Show full finding
Safety note
Multiple pregnancy occurred and one ovarian-hyperstimulation case involved concomitant clomiphene.
Two-year comparison of pulsatile GnRH and gonadotropin therapy in men with hypogonadotropic hypogonadism
1988PMID 3142911
- Population / Model
- Men with hypogonadotropic hypogonadism
- Dose / Duration / Finding
In a sequential comparison among men with isolated hypogonadotropic hypogonadism who had previously received exogenous gonadotropin (hCG/hMG) therapy, subsequent treatment with pulsatile GnRH for up to 18 months produced further testicular growth, exceeding the testicular size previously achieved with gonadotropin therapy by approximately 53%.
Show full finding
Safety note
Specialist fertility treatment; limited sample and older methods.
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries(1)
FDA orphan-drug designation and approval record for gonadorelin acetate (Lutrepulse)
1989- Population / Model
- Historical FDA orphan-drug approval record
- Dose / Duration / Finding
FDA records document marketing approval on October 10, 1989 for induction of ovulation in women with hypothalamic amenorrhea due to deficient or absent endogenous GnRH secretion.
Safety note
The historical record does not by itself establish current marketing availability.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-07-26.
Follow research updates for Gonadorelin Acetate
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.